Abstract：
BACKGROUND: Intermittent fasting (IF) is a diet strategy with alternate intervals of calorie reduction and normal eating. Despite its beneficial effects on weight loss and cardiometabolic risk factors, the effect of IF on liver function tests (LFTs) remains unclear.
OBJECTIVE: This study aimed to investigate the effect of IF on LFTs through a systematic review and meta-analysis of randomized clinical trials.
METHODS: An electronic search was performed using predefined search terms in databases including PubMed, Scopus, and ISI Web of Science until February 2023.
METHODS: The studies were selected according to PRISMA guidelines, and the risk of bias was assessed for the randomized controlled trials.
METHODS: The results of this study are reported as weighted mean differences (WMDs) with 95% CIs. Fourteen RCTs were included in the meta-analysis, with a total sample size of 908. IF significantly reduced alanine aminotransferase (ALT) (WMD: -2.88, 95% CI: -4.72 to -1.04, P-value = .002) and aspartate aminotransferase (AST) levels (WMD: -1.67, 95% CI: -3.12 to -0.22, P-value = .024). The results of the subgroup analysis showed that the impact of IF was significant in both the nonalcoholic fatty liver disease and the healthy groups for ALT. The effects of IF on the serum gamma-glutamyl transpeptidase (GGT) level were significant (WMD: -3.19, 95% CI: -6.00 to -0.39, P-value = .026), but there were no significant changes in the alkaline phosphatase (ALP) level (WMD: 1.06, 95% CI: -0.23 to 2.34, P-value = .106). Furthermore, no substantial heterogeneity between studies was reported.
CONCLUSIONS: IF can improve ALT, AST, and GGT levels but not ALP enzyme levels and may have a benefit on liver function.
BACKGROUND: PROSPERO registration no. CRD42023396211.
OBJECTIVE: This study aimed to investigate the effect of IF on LFTs through a systematic review and meta-analysis of randomized clinical trials.
METHODS: An electronic search was performed using predefined search terms in databases including PubMed, Scopus, and ISI Web of Science until February 2023.
METHODS: The studies were selected according to PRISMA guidelines, and the risk of bias was assessed for the randomized controlled trials.
METHODS: The results of this study are reported as weighted mean differences (WMDs) with 95% CIs. Fourteen RCTs were included in the meta-analysis, with a total sample size of 908. IF significantly reduced alanine aminotransferase (ALT) (WMD: -2.88, 95% CI: -4.72 to -1.04, P-value = .002) and aspartate aminotransferase (AST) levels (WMD: -1.67, 95% CI: -3.12 to -0.22, P-value = .024). The results of the subgroup analysis showed that the impact of IF was significant in both the nonalcoholic fatty liver disease and the healthy groups for ALT. The effects of IF on the serum gamma-glutamyl transpeptidase (GGT) level were significant (WMD: -3.19, 95% CI: -6.00 to -0.39, P-value = .026), but there were no significant changes in the alkaline phosphatase (ALP) level (WMD: 1.06, 95% CI: -0.23 to 2.34, P-value = .106). Furthermore, no substantial heterogeneity between studies was reported.
CONCLUSIONS: IF can improve ALT, AST, and GGT levels but not ALP enzyme levels and may have a benefit on liver function.
BACKGROUND: PROSPERO registration no. CRD42023396211.
摘要：
背景：间歇性禁食（IF）是一种饮食策略，具有减少卡路里和正常饮食的交替间隔。尽管它对减肥和心脏代谢危险因素有有益的影响，IF对肝功能检查(LFTs)的影响尚不清楚.
目的：本研究旨在通过对随机临床试验的系统评价和荟萃分析来研究IF对LFTs的影响。
方法：使用包括PubMed、Scopus,和ISIWebofScience，直到2023年2月。
方法：根据PRISMA指南选择研究，并对随机对照试验的偏倚风险进行了评估.
方法：本研究的结果报告为加权平均差（WMD），CI为95％。14项RCT纳入荟萃分析，总样本量为908。如果显着降低丙氨酸氨基转移酶（ALT）（WMD：-2.88，95％CI：-4.72至-1.04，P值=.002）和天冬氨酸氨基转移酶（AST）水平（WMD：-1.67，95％CI：-3.12至-0.22，P值=.024）。亚组分析的结果表明，IF在非酒精性脂肪性肝病和健康组对ALT的影响均显着。IF对血清γ-谷氨酰转肽酶（GGT）水平的影响是显着的（WMD：-3.19，95％CI：-6.00至-0.39，P值=.026），但碱性磷酸酶（ALP）水平无明显变化（WMD：1.06，95％CI：-0.23至2.34，P值=.106）。此外，没有报道研究之间的实质性异质性.
结论：如果可以改善ALT，AST,和GGT水平，而不是ALP酶水平，可能对肝功能有益。
背景：PROSPERO注册号。CRD42023396211。
目的：本研究旨在通过对随机临床试验的系统评价和荟萃分析来研究IF对LFTs的影响。
方法：使用包括PubMed、Scopus,和ISIWebofScience，直到2023年2月。
方法：根据PRISMA指南选择研究，并对随机对照试验的偏倚风险进行了评估.
方法：本研究的结果报告为加权平均差（WMD），CI为95％。14项RCT纳入荟萃分析，总样本量为908。如果显着降低丙氨酸氨基转移酶（ALT）（WMD：-2.88，95％CI：-4.72至-1.04，P值=.002）和天冬氨酸氨基转移酶（AST）水平（WMD：-1.67，95％CI：-3.12至-0.22，P值=.024）。亚组分析的结果表明，IF在非酒精性脂肪性肝病和健康组对ALT的影响均显着。IF对血清γ-谷氨酰转肽酶（GGT）水平的影响是显着的（WMD：-3.19，95％CI：-6.00至-0.39，P值=.026），但碱性磷酸酶（ALP）水平无明显变化（WMD：1.06，95％CI：-0.23至2.34，P值=.106）。此外，没有报道研究之间的实质性异质性.
结论：如果可以改善ALT，AST,和GGT水平，而不是ALP酶水平，可能对肝功能有益。
背景：PROSPERO注册号。CRD42023396211。
